



July 4, 2023

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 ('Listing Regulations').

We are pleased to enclose a Press release regarding receipt of tentative approval from the U.S. FDA for the Company's Abbreviated New Drug Application, Dolutegravir Tablets for Oral Suspension, 5 mg, to market a generic equivalent of Tivicay PD[®] Tablets for Oral Suspension, 5 mg of ViiV Healthcare Company.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl: a/a

Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir Tablets for Oral Suspension

Mumbai, Baltimore, July 04, 2023: Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA), Dolutegravir Tablets for Oral Suspension, 5 mg, to market a generic equivalent of Tivicay PD[®] Tablets for Oral Suspension, 5 mg of ViiV Healthcare Company. This product will be manufactured at Lupin's Nagpur facility in India.

Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD[®]) had estimated annual sales of USD 1 million in the U.S. (IQVIA MAT March 2023).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications

Email: shwetamunjal@lupin.com

*Safe Harbor Statement

Tivicay PD[®] is a registered trademark of ViiV Healthcare Company